The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
FDA approves POLARx Cryoablation System for treating paroxysmal atrial fibrillation
The FDA has approved the POLARx Cryoablation System for treating paroxysmal atrial fibrillation. Meanwhile, Amneal Pharmaceuticals filed a New Drug Application for PEMRYDI RTU, aimed at non-squamous non-small cell lung cancer and malignant pleural mesothelioma. The global pleural diseases market is projected to grow, with thoracentesis expected to dominate treatment options, particularly in North America, driven by increasing healthcare investments and a rising geriatric population.